Galapagos

Generaal De Wittelaan L 11A3

2800 Mechelen

BE

Galapagos

Foundation date

30/06/1999

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.

Upcoming events

Latest news

  • argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • Galapagos appoints Simon Sturge to its Board of Directors

    Tuesday September 19th 2023

  • 13th Investment for HERAN Partners: Broken String Biosciences (UK)

    Tuesday September 19th 2023